Ocular Therapeutix (OCUL) Capital Expenditures (2013 - 2026)

Ocular Therapeutix's Capital Expenditures history runs 14 years deep, the most recent figure standing at $1.3 million for Q1 2026.

• In Q1 2026, Capital Expenditures fell 31.35% year-over-year to $1.3 million; the TTM figure through Mar 2026 stood at $568000.0 (down 68.43% YoY), while the FY2025 annual figure was $1.2 million, up 870.25% from the prior year.
• Capital Expenditures was $1.3 million for Q1 2026 at Ocular Therapeutix, up from -$8.0 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $6.0 million in Q3 2025 to a low of -$8.0 million in Q4 2025.
• Historically, Capital Expenditures has averaged $373705.9 across 5 years, with a median of $276000.0 in 2022.
• The sharpest annual moves came in 2023 and 2025: Capital Expenditures surged 15335.48% in 2023, then plunged 17871.11% in 2025.
• A 5-year view of Capital Expenditures shows it stood at $3.2 million in 2022, then slumped by 273.32% to -$5.6 million in 2023, then jumped by 100.8% to $45000.0 in 2024, then slumped by 17871.11% to -$8.0 million in 2025, then surged by 116.59% to $1.3 million in 2026.
• The last three Capital Expenditures figures came in at $1.3 million (Q1 2026), -$8.0 million (Q4 2025), and $6.0 million (Q3 2025), per Business Quant data.